tbuckley/cabot-search huggingface dataset:
QOLP-32. PATTERNS OF CARE AT END OF LIFE IN PATIENTS WITH GLIOMA
Authors: Marissa Barbaro, Craig Blinderman, Fabio Iwamoto, Teri Kreisl, Mary Welch, Yazmin Odia, Laura Donovan, Katharine Evans, Andrew Lassman
Journal: Neuro-Oncology (2019)

Abstract OBJECTIVE To understand patterns of care at end of life in glioma patients. BACKGROUND Patients with gliomas often inquire about end-of-life issues. Understanding common clinical outcomes of tumor progression and end-of-life circumstances may reduce anxiety among patients and caregivers and inform care planning. METHODS Following IRB approval, we retrospectively analyzed circumstances surrounding death among patients with intracranial gliomas at Columbia University Irving Medical Center from 1/2014-2/2019, including immediate cause and location of death and implementation of palliative measures. Information unavailable from the medical record was supplemented by caregivers. RESULTS Data were available for 152 patients (95 men, 57 women; median age at death 61.5 years). Failure to thrive with transition to supportive care (n=117, 77%) was the most common immediate cause of death. Others included infection (19, 13%; with pulmonary (12, 8%), urinary tract (5, 3%), CNS (4, 3%), and GI (2, 1%) sources); seizures (8, 5%); intracerebral hemorrhage (5, 3%); cerebral edema (4, 3%); pulmonary embolism (4, 3%); autonomic failure (2, 1%); hemorrhagic shock (2, 1%); respiratory failure of unknown cause (2, 1%); pulmonary edema (1, 1%); and cardiac arrhythmia (1, 1%). Ten patients had multiple causes of death. Seventy-three patients (48%) died at home with hospice. Other locations were inpatient hospice (40, 26%); acute care hospital (34, 22%) including 27 (18%) with and 7 (5%) without comfort measures; skilled nursing facility (4, 3%) including 3 (2%) with and 1 (1%) without comfort measures; or religious facility (1, 1%) with comfort measures. Acute cardiac and/or pulmonary resuscitation was performed in 20 patients (13%); 8 (5%) died with no comfort measures. CONCLUSIONS Failure to thrive with transition to supportive care was the most common (77%) immediate cause of death followed by infection (13%). Hospice and/or palliative measures were implemented in 95% of patients, though resuscitative efforts were performed in 13%.
Plasmablastic Lymphoma - Experience with Infusional EPOCH Chemotherapy from India
Authors: Jayachandran PK, Arun Kumar Rajan, Nikita Mehra, Gangothri Selvarajan, Joshi Archit Girishchandra, Parathan Karunakaran, Manikandan Dhanushkodi, Venkatraman Radhakrishnan, Krishnarathinam Kannan, Trivadi S Ganesan, Tenali Gnana Sagar
Journal: Blood (2019)
Atrial scar quantification via multi-scale CNN in the graph-cuts framework
Authors: Lei Li, Fuping Wu, Guang Yang, Lingchao Xu, Tom Wong, Raad Mohiaddin, David Firmin, Jennifer Keegan, Xiahai Zhuang
Journal: Medical Image Analysis (2019)

Late gadolinium enhancement magnetic resonance imaging (LGE MRI) appears to be a promising alternative for scar assessment in patients with atrial fibrillation (AF). Automating the quantification and analysis of atrial scars can be challenging due to the low image quality. In this work, we propose a fully automated method based on the graph-cuts framework, where the potentials of the graph are learned on a surface mesh of the left atrium (LA) using a multi-scale convolutional neural network (MS-CNN). For validation, we have included fifty-eight images with manual delineations. MS-CNN, which can efficiently incorporate both the local and global texture information of the images, has been shown to evidently improve the segmentation accuracy of the proposed graph-cuts based method. The segmentation could be further improved when the contribution between the t-link and n-link weights of the graph is balanced. The proposed method achieves a mean accuracy of 0.856 ± 0.033 and mean Dice score of 0.702 ± 0.071 for LA scar quantification. Compared to the conventional methods, which are based on the manual delineation of LA for initialization, our method is fully automatic and has demonstrated significantly better Dice score and accuracy (p < 0.01). The method is promising and can be potentially useful in diagnosis and prognosis of AF.
Simultaneous Kinase Inhibition with Ibrutinib and BCL2 Inhibition with Venetoclax As a Therapeutic Strategy for Acute Lymphoblastic Leukemia
Authors: Christopher A. Eide, Stephen E Kurtz, Andy Kaempf, Nicola Long, Jessica Leonard, Bill H. Chang, Motomi Mori, Brian J. Druker, Jeffrey W. Tyner
Journal: Blood (2019)
An Update on rFVIIa Use in Females with Rare Bleeding Disorders
Authors: Meera B. Chitlur, Manuel Carcao, David Cooper, Shilpa Jain, Kaan Kavakli, Bryce Kerlin, Skye Peltier, Man-Chiu Poon, Hossam Saad, Amy Shapiro
Journal: Blood (2019)
Progression-Free Survival and Overall Survival Among a Patient Cohort of Relapsed/Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom
Authors: Martine Bagot, Timothy Illidge, Nicola Pimpinelli, Mehul Dalal, Athanasios Zomas, Chalid Assaf, Nathalie Waser, Zhouqin He, Tina Li, Robert Sambrook, Fabrizio Trinchese, Meredith Little, Nawal Bent-Ennakhil, Pablo L. Ortiz-Romero
Journal: Blood (2019)
Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events
Authors: Subodh Verma, Stephen C. Bain, John B. Buse, Thomas Idorn, Søren Rasmussen, David D. Ørsted, Michael A. Nauck
Journal: JAMA Cardiology (2019)

After the occurrence of nonfatal cardiovascular events, recurrent events are highly likely. Most cardiovascular outcomes trials analyze first events only; extending analyses to first and recurrent (total) events can provide clinically meaningful information.To investigate whether liraglutide is associated with reduced first and recurrent total major adverse cardiovascular events (MACE) compared with placebo among patients with type 2 diabetes and high risk of cardiovascular events.This post hoc analysis of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) randomized, double-blind, clinical trial included data from patients with type 2 diabetes who had established or were at high risk for cardiovascular disease at 410 sites in 32 countries from August 2010, to December 2015. Data analysis was performed from August 15, 2016, to July 5, 2019.Patients were randomized 1:1 to receive liraglutide (up to 1.8 mg per day) or placebo, both with standard care, for 3.5 to 5.0 years.Assessed outcomes were MACE (cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke), expanded MACE (primary MACE plus coronary revascularization and hospitalization for heart failure or unstable angina pectoris), and the individual end points.The 9340 LEADER trial participants (6003 [64.3%] male; mean [SD] age, 64.3 [7.2] years) experienced 1605 total MACE (1302 first and 303 recurrent events; median follow-up, 3.8 years [range, 0-5.2 years]). Patients who experienced any MACE were older (1 MACE: mean [SD] age, 65.6 [8.0] years; >1 MACE: 65.7 [7.9] years) and had diabetes for longer duration (1 MACE: mean [SD] duration, 13.4 [8.3] years; >1 MACE: 14.4 [8.7] years) compared with patients without MACE (mean [SD] age, 64.1 [7.1] years; mean [SD] duration, 12.7 [7.9] years). Fewer first and recurrent MACE occurred in the liraglutide group (n = 4668; 608 first and 127 recurrent events) than in the placebo group (n = 4672; 694 first and 176 recurrent events). Liraglutide was associated with a 15.7% relative risk reduction in total MACE (hazard ratio [HR], 0.84; 95% CI, 0.76-0.93) and a 13.4% reduction in total expanded MACE (HR, 0.87; 95% CI, 0.81-0.93) compared with placebo. For most individual cardiovascular end points, liraglutide was associated with lower risk vs placebo.These results suggest that liraglutide treatment is associated with reduced total MACE compared with placebo among patients with type 2 diabetes and high risk of cardiovascular events. This analysis supports the findings of an absolute benefit of liraglutide treatment with respect to the overall burden of cardiovascular events in this high-risk patient population.ClinicalTrials.gov identifier: NCT01179048.
RTHP-03. FRAME-BASED AND MASKED STEREOTACTIC RADIOSURGERY: A PATIENT EXPERIENCE COMPARISON WITH THE GAMMA KNIFE ICON
Authors: Troy Dawley, Zaker Rana, Anuj Goenka, Michael Schulder
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Patients undergoing stereotactic radiosurgery (SRS) for intracranial pathology have two treatment options: frame-based (FB) versus masked (MB). There is sparse information on a patient’s experience between the two types and to what extent a patient’s diagnosis will predict their SRS experience. METHODS A retrospective analysis of patients who completed a questionnaire of their experience after SRS using the Gamma Knife Icon was completed. RESULTS Fifty-eight patients completed the questionnaire, 60% were FB and 40% MB. The average age was 63.3 + 15.3 years, 40% were male. Of the patients treated with a FB technique, 51% didn’t find SRS to be uncomfortable. Comparatively, 91% of MB patients didn’t find SRS to be uncomfortable. Patients who underwent FB treatment rated their pain of frame placement on a visual analog scale (VAS) 1–3, 24%, VAS 4–6, 46%, VAS 7–10, 30%. Eight patients answered that they didn’t tolerate the procedure as expected, most of which were treated using a FB method (87%). Compared to previous surgery or SRS, five patients found their experience of SRS wasn’t tolerable, while 93% of patients would consider repeat SRS. All patients treated felt adequately informed about the procedure. The patient experience of discomfort during SRS and their evaluation of pain during frame placement between patients treated for benign versus malignant lesions (discomfort: 59% vs. 22%, respectively and median VAS pain: 6 + 2.67, 4.5 + 1.99, respectively) determined a benign diagnosis had more discomfort during SRS compared to a malignant diagnosis. Pain during frame placement was similar for both diagnoses. CONCLUSION Patients experienced frame-based SRS as more uncomfortable than mask-based treatment. Benign pathologies appeared to have more discomfort compared to malignant pathologies. All patients of both techniques felt adequately informed about their procedure.
Combination of the MEK Inhibitor Trametinib and Pyrvinium Pamoate Efficiently Targets RAS Pathway-Mutated Acute Myeloid Leukemia in Preclinical Models
Authors: Justine Decroocq, Rudy Birsen, Jordi Mano, Guillemette Fouquet, Mathilde Gotanègre, Laury Poulain, Sarah Mouche, Anne-Sophie Alary, Adrien Grenier, Fetta Mazed, Johanna Mondesir, Nicolas Chapuis, Aicha Boughalem, Marc Le Lorc'h, Ivan C Moura, Olivier Hermine, Isabelle Radford-Weiss, Jean-Emmanuel Sarry, Eric Pasmant, Olivier Kosmider, Didier Bouscary, Jerome Tamburini
Journal: Blood (2019)
Mutational Dynamics and Evolutionary Divergence in DLBCL: A Call for Relapse Sampling
Authors: Jillian F. Wise, Sigve Nakken, Chloé B Steen, Daniel Vodák, Gunhild Trøen, Bjarne Johannessen, Ole Christian Lingjærde, Vera Hilden, Yngvild Nuvin Blaker, Baoyan Bai, Lars B. Aasheim, Annika Pasanen, Suzanne Lorenz, Anita Sveen, Ragnhild Lothe, Ola Myklebost, Sirpa Leppa, Leonardo Meza-Zepeda, Klaus Beiske, Michael S. Lawrence, Eivind Hovig, June Helen Myklebust, Erlend B. Smeland, Harald Holte
Journal: Blood (2019)
GENE-52. ANALYSIS OF RECURRENT MUTATIONS WITHIN CANCERS REVEALS PATTERNS OF DIRECTIONAL EVOLUTION IN BRAIN TUMORS
Authors: Asli Küçükosmanoglu, Carolien L Van Der Borden, David Noske, Tom Wurdinger, Bart Westerman
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Intratumor genetic heterogeneity is commonly caused by a stochastic evolution, but can also show remarkable selectivity resulting in directional evolution. We hypothesized that directional evolution is driven by its genetic onset-stage. This process could enforce already existing traits resulting in an enhancement of linear pathways rather than the complementary/parallel evolution. METHODS We generated a prediction model for directional evolution based on its genetic onset-stage. We performed a comprehensive analysis of 16 different tumor types of ~10,000 patients of whole-exome sequencing and copy number variation, obtained from The Cancer Genome Atlas. RESULTS We found in 5% of the patients that directional evolution occurs on a fixed genetic onset stage. There is a strong relationship between the frequencies of directional evolution and the frequencies of commonly co-occurring mutations in the onset stage. These co-occurring mutations are frequently observed in the same chromosomal region and occasionally in the same pathway. Brain tumors show a frequent directional evolution towards EGFR mutations and to a lesser extent PIK3CA mutations. CONCLUSION Given these strong correlations and since directional evolution is apparently a highly selective process, our prediction model could predict more effective therapies by choosing therapies targeting both the mutated gene that is affected by directional evolution as well as the commonly occurring co-mutated genes.
Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
Authors: Nitin Jain, Michael J Keating, Philip A. Thompson, Alessandra Ferrajoli, Jan A. Burger, Gautam M. Borthakur, Koichi Takahashi, Zeev E. Estrov, Nathan H. Fowler, Tapan M. Kadia, Marina Y Konopleva, Yesid Alvarado, Musa Yilmaz, Courtney D. DiNardo, Prithviraj Bose, Maro Ohanian, Naveen Pemmaraju, Elias Jabbour, Koji Sasaki, Rashmi Kanagal-Shamanna, Keyur Patel, Jeffrey L. Jorgensen, Sa A Wang, Naveen Garg, Xuemei Wang, Katrina Sondermann, Nichole Cruz, Chongjuan Wei, Ana Ayala, William Plunkett, Hagop M. Kantarjian, Varsha Gandhi, William G. Wierda
Journal: Blood (2019)
Results of a Multicentre, Randomized, Controlled Open-Label Study on the Use of Anti-T-Lymphocyte Globulin (ATLG) and Rituximab for Immunomodulation of Graft-Versus-Host Disease (GvHD) and Graft Failure (GF) in Patients with Non-Malignant Disorders
Authors: Mattia Algeri, Stefania Galimberti, Maria Ester Bernardo, Attilio Rovelli, Marco Zecca, Giorgio La Nasa, Sarah Marktel, Pietro Merli, Alice Bertaina, Daria Pagliara, Emilia Boccieri, Francesca Del Bufalo, Stefania Gaspari, Giulia Capitoli, Maria Grazia Valsecchi, Franco Locatelli
Journal: Blood (2019)
1q21 Gain May Challenge the Role of t(4;14) As an Adverse Prognostic Marker of Multiple Myeloma
Authors: Chenxing Du, An Gang, Yan Xu, Xuehan Mao, Yuting Yan, Jiahui Liu, Huishou Fan, Weiwei Sui, Shuhui Deng, Li Zengjun, Chengwen Li, Shuhua Yi, Mu Hao, Dehui Zou, Fenghuang Zhan, Yu-Tzu Tai, Kenneth C. Anderson, Lugui Qiu
Journal: Blood (2019)
TMIC-24. COLONY STIMULATING FACTOR 1 INHIBITION DECREASES TUMOR GROWTH AND MACROPHAGE INFILTRATION, AND INCREASES NEUTROPHIL INFILTRATION IN XENOGRAFT MICE MODELS OF GLIOBLASTOMA
Authors: Sabbir Khan, Yuji Piao, Sandeep Mittal, Kain McGee, Soon Park, Kristin Alfaro-Munoz, Veerakumar Balasubramaniyan, John DeGroot
Journal: Neuro-Oncology (2019)

Abstract Glioblastoma (GBM) is the most common, highly aggressive and lethal primary brain tumor in adults, and has a median overall survival ranging from 12 to 15 months. Several human cancers including glioma are infiltrated with numerous immune cell types which play a critical role in tumor growth, invasion and resistance to treatment. Previous studies, including our group, have shown that resistance to anti-VEGF therapy is associated with myeloid cell infiltration and mesenchymal transition in GBM. Notably, most glioma patients have shown increase in CD68+ cells due to overproduction of colony stimulating factor 1 (CSF-1) by tumor cells, a growth factor for macrophages. Therefore, we hypothesized that CSF-1 inhibition may reduce macrophage and/or myeloid cell infiltration in glioma, thereby increasing animal survival as monotherapy or in combination with VEGF inhibitors in xenograft GBM mouse models. We tested two CSF-1R inhibitors (AZD 7507 and JNJ-28312141) alone and in combination with VEGF inhibition to prevent macrophage infiltration in xenograft GBM mouse models. CSF-1R and VEGF inhibitors reduced macrophage infiltration (F4/80 staining), tumor volume, and mesenchymal transition (YKL-40 staining), and there was a marginal survival benefit in this model. Interestingly, despite significant reduction in tumor macrophages, we observed a significant increase in neutrophil infiltration and hypoxia (HIF1α staining), particularly in the combinatorial treated. Considering these observations, we further evaluated tumor-associated neutrophil (TAN) infiltration in GBM patient tumors by fluorescence-activated cell sorting (FACS). FACS-isolated TANs were identified as CD11b+/CD15+/CD66b+ triple positive. Our results shown that the infiltrating TAN population vary from 0.5 to 5% in GBM patient tumors. Detailed characterization of TAN population and polarization in patient tumors are ongoing. Our findings revealed that CSF-1 and VEGF inhibition reduced macrophage infiltration and tumor growth, but significantly increased TAN infiltration which will likely hamper the potential therapeutic benefit of anti-CSF1-directed inhibitors.
Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial
Authors: Kirsten Fischer, Matthias Ritgen, Othman Al-Sawaf, Sandra Robrecht, Maneesh Tandon, Anna-Maria Fink, Anke Schilhabel, Thomas Stübig, Monika Brüggemann, Yanwen Jiang, William Schary, Barbara F. Eichhorst, Clemens-Martin Wendtner, Eugen Tausch, Karl-Anton Kreuzer, Anton W Langerak, Valentin Goede, Sebastian Böttcher, Stephan Stilgenbauer, Michael Kneba, Michael Hallek
Journal: Blood (2019)
Vaping—Seeking Clarity in a Time of Uncertainty
Authors: Stephen R. Baldassarri, David A. Fiellin, Abigail S. Friedman
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Differences in Admission Rates Among Patients Treated with Apixaban Vs. Warfarin for Venous Thromboembolism in the Emergency Department
Authors: Steven Deitelzweig, Patrick Hlavacek, Jack Mardekian, Lisa Rosenblatt, Cristina Russ, Kenneth Tuell, Melissa Lingohr-Smith, Jay Lin, Jennifer D Guo
Journal: Blood (2019)
TMOD-24. DEVELOPMENT OF A NOVEL IN VIVO MODEL OF LUNG-TO-BRAIN METASTASIS PROGRESSION
Authors: Mohini Singh, Naema Nayyar, Megha Subramanian, Priscilla Brastianos
Journal: Neuro-Oncology (2019)

Abstract Brain metastases (BM) are the most common neoplasm to affect the adult central nervous system, occurring ten times more frequently than primary brain tumor. BM develop in 40–50% of advanced lung adenocarcinoma (LUAD), and the lack of durable response to chemotherapy, immunotherapy, or targeted therapy will result in death within a year of BM diagnosis. Despite the high burden of disease, dismal prognosis, and the increase in incidence over time, the biological underpinnings of BM remain poorly understood due to both the difficulty of obtaining a sizable collection of metastatic tissue samples as well as a lack of clinically relevant models. As such, it is possible that the inability to properly study this disease may result in metastasis driver-genes remaining undiscovered. Typical models of BM utilize direct implantation of tumor cells into the mouse brain, or inoculation into the blood via intracardiac/intracarotid injections; these routes are invasive and cannot fully recapitulate the entirety of the metastatic cascade. Here we present a novel, non-invasive method to develop primary lung tumors and brain metastases. A 10µL tumor cell suspension in phosphate-buffered saline was applied to the nostrils of lightly anesthetized mice, allowing direct deposit of cells into the lungs. Mice were monitored with bioluminescence imaging bi-weekly and culled at 2.5–3 months post-inoculation. Lungs and brains were also removed and imaged, where tumors in both organs were observed. Further research is necessary to elucidate either the linear or parallel progression of tumor formation within this model. Nonetheless, our technique presents a novel preclinical tool to interrogate the metastatic process, allowing validation of genetic drivers as well as therapeutic screening.
Meta-Analyses of Clinical Trials Comparing the Progression Free Survival and Adverse Events in Treated Versus Observed Patients with Smoldering and Indolent Multiple Myeloma
Authors: Fahrettin Covut, Tariq Zuheir Kewan, Apoorva Anandan, Folashade Otegbeye, James Driscoll, Marcos de Lima, Ehsan Malek
Journal: Blood (2019)
Bortezomib-Based Induction, Augmented Conditioning with Busulfan and Melphalan + ASCT and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma: Long-Term Results of the National Canadian Mcrn-001 Study
Authors: Donna E Reece, Giovanni Piza Rodriguez, Mariela A Pantoja, Darrell J White, Christopher P Venner, Julie Stakiw, Michael Sebag, Terrance Comeau, Kevin Song, Jean Roy, Martha L Louzada, Arleigh McCurdy, Vishal Kukreti, Suzanne Trudel, Anca Prica, Rodger E Tiedemann, Harminder K Paul, Christine I Chen
Journal: Blood (2019)
AB0050 Minor salivary gland biopsy findings in patients with rheumatoid arthritis
Authors: E Dalkilic, Y Karakoc, E Ozturk, S Balaban, M Dogru, A Ozkan, M Gullulu
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Secondary Sjogren’s syndrome (SS) is one of the major extraarticular manifestations of the patients with rheumatoid arthritis (RA). The prevalence of SS in RA varies between 11% and 62% depending on the definition used. Salivary gland histopathology has been considered to be the most disease spesific test for diagnosis of SS. <h3>Objectives</h3> In this study, we aimed to investigate the histopatholojic features of minor salivary gland biopsies in RA patients with disease duration longer than 3 years and with no subjective complains of xerophthalmia or xerostomia. <h3>Methods</h3> Eighteen (11 male,7 female, mean age 49) RA patients with no subjective complains of ocular or oral dryness were included into study. Minor salivary gland biopsy was performed to all patients and lymphocytic infiltration of a cluster of at least 50 lymphocyte in the gland area of 4 mm<sup>2</sup> accepted as a diagnostic criteria for SS. We also performed Schirmer’s test, fluorescein break up time and Rose Bengal staining. The serum levels of rheumatoid factor (RF), anti-SS-A and anti-SS-B antibodies were all assayed. <h3>Results</h3> <h3>Conclusion</h3> Subclinical SS may be developed in RA patients with no subjective complains of ocular and oral dryness.